MDM2 and urothelial carcinoma: Amplification of MDM2 was detected most frequently (1.4%; 3 lung cancer, 1 melanoma, 2 liposarcoma, 2 urothelial carcinoma samples), which is reported to be associated with hyperprogressive disease after immunotherapy treatment [44].